Hello, everyone, and top of the morning to you. A lovely day is emerging here on the Pharmalot corporate campus, although this will be a busy one as we prepare for those meetings and deadlines. We know you relate, so please join us for a cup of stimulation - our flavor today is Rain Forest Nut. Or grab a bottle of water if you prefer. Meanwhile, here are some tidbits from around the world, such as it is. Hope your day is swell and you achieve your goals. See you later...
SEC Expected To Act On Whistleblower Program (Washington Post)
Deaths In Pfizer Arthritis Drug Trial Are Under A Microscope (Reuters)
Vertex And Its Small, But Experienced Sales Force (Dow Jones)
Watson Pays $562M For Generic Drug Developer (Reuters)
Bayer and J&J's Xarelto Prevented Repeat Strokes In Analysis (Bloomberg News)
Novartis Drug Offers Pain Relief In Gouty Arthritis (Reuters)
Nestle Health Science Buys Prometheus (Pharma Times)
Pfizer Upgrades Injectable Plant (InPharm)
Roskamp Institute Begins Phase III For Alzheimer's Candidate (Sarasota Herald-Tribune)
EDITOR’S NOTE: Please check this post for updates throughout the morning